Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta. Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior ...

In September, Pfizer withdrew Oxbryta (voxelotor) for sickle cell disease, added via its $5.4 billion buyout of Global Blood Therapeutics in 2022. Starboard contended that Pfizer overpaid for its ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B acquisition of Global Blood Therapeutics in 2022. "For large pharma ...

and pulling its sickle cell disease treatment Oxbryta due to deaths in its clinical trials. Smith did not make any specific prescriptions for Pfizer or its management at the presentation.

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...